In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA University of Tokyo Admits Patient Information on SIGN Trial Leaked to Novartis
March 17, 2014
-
REGULATORY Eligibility for Key Pricing Premium Up for Discussion: Govt
March 17, 2014
-
BUSINESS LEO Pharma to Carefully Ponder When to Begin Solo Marketing in Japan: Local Head
March 14, 2014
-
BUSINESS Otsuka to Disclose Patient-Level Clinical Trial Data
March 13, 2014
-
BUSINESS AstraZeneca, Osaka University Aim to Resurrect Ditched Drug Candidates
March 13, 2014
-
ORGANIZATION PhRMA “Disappointed” by Rule Changes for Foreign Price Adjustments: New Japan Committee Chair
March 12, 2014
-
REGULATORY Revisions of Prefectural Disaster Plans for Drug Distribution Almost Complete
March 11, 2014
-
BUSINESS Pfizer Japan Logs 1.2% Sales Increase in FY2013
March 10, 2014
-
BUSINESS Takeda Submits NDA for Once-Weekly DPP-4 Inhibitor Trelagliptin
March 10, 2014
-
ORGANIZATION FPMAJ Generic Guidelines Urge Makers to Create “Stable Supply” Officer Post
March 7, 2014
-
BUSINESS 28% of Mainstays to Face New Price Cuts for Long-Listed Drugs: Jiho Survey
March 7, 2014
-
BUSINESS New Price Cuts for Long-Listed Drugs to Pummel MTPC, Astellas: Jiho Tally
March 6, 2014
-
REGULATORY FY2014 NHI Revision Sees Price Cut of 5.64% without Tax Surcharges, 1,118 Long-Listed Products Subject to New Rule
March 5, 2014
-
BUSINESS Samsca Tops January “Mind Share” Ranking in HP Market
March 5, 2014
-
BUSINESS Takeda Apologizes for Violating Promotion Code, Inappropriate Expressions in Ads
March 4, 2014
-
BUSINESS Takeda’s Next Leader Weber to Take Up COO Role on April 1
March 3, 2014
-
ACADEMIA JAMS’s Newly Revised COI Management Guidelines Impose Stricter Rules
February 28, 2014
-
BUSINESS 72 Drug Makers Provided 483 Billion Yen in Funding to Medical and Research Institutions in FY2012
February 27, 2014
-
BUSINESS Quintiles to Increase Contract Sales Reps in Japan: Global Commercial Head Evangelista
February 26, 2014
-
BUSINESS Takeda to Realign Japan Sales Team
February 25, 2014
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…